Clarivate Epidemiology’s coverage of BPH comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of BPH for each country, as well as…
Clarivate Epidemiology’s coverage of male hypogonadism comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key BPH patient populations covering 171 countries and more than 99% of…
Clarivate Epidemiology’s coverage of male lower urinary tract symptoms (LUTS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of male lower urinary tract symptoms (LUTS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of male lower urinary tract symptoms (LUTS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of male lower urinary tract symptoms (LUTS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of male lower urinary tract symptoms (LUTS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of male lower urinary tract symptoms (LUTS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of…
Clarivate Epidemiology’s coverage of male LUTS comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of male LUTS for each country,…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key male LUTS patient populations covering 171 countries and more than…
Clarivate Epidemiology’s coverage of giant cell arteritis (GCA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of gastroesophageal reflux disease (GERD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United…